Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04753983 Withdrawn - Refractory Epilepsy Clinical Trials

A Study to Evaluate fMRI of Active DBS Stimulation in Epilepsy

Start date: September 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to use functional imaging to study the mechanisms of the anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS).

NCT ID: NCT04737174 Withdrawn - Epilepsy; Seizure Clinical Trials

ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

Start date: March 25, 2021
Phase: Phase 2
Study type: Interventional

Phase 2A single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and pharmacokinetics of ES-481 as adjunctive therapy in glioma-associated epilepsy and to assess for potential anti-tumorigenic effects.

NCT ID: NCT04546711 Withdrawn - Epilepsy Clinical Trials

Energy Expenditure and Quality of Life in Epilepsy

Start date: June 2023
Phase:
Study type: Observational

The main objectives of this study are to investigate the influence of the ketogenic diet (KD), standard care for patients assisted in the UW Health Adult Epilepsy Dietary Therapy Clinic, on changes in the frequency and severity of seizures, QoL, energy substrate metabolism, body energy expenditure components, fat mass and fat-free mass in adults with epilepsy. To achieve this objective, twenty-five male and female participants between the ages of 18 and 45 years (or over 18 years for remote participation), who accepted to initiate the KD as a standard of care prescribed by their physician, will be recruited according to inclusion/exclusion criteria. Participants will be on study for 6 months.

NCT ID: NCT04406948 Withdrawn - Clinical trials for Children and Adolescents With Resistant Epilepsies

Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

EudraCT: 2018-003887-29 Objective:To evaluate the safety and efficacy of: MGCND00EP1 from MGC PHARMACEUTICALS d.o.o. Study Design: Randomized, double blind, placebo controlled parallel grouped study Sample Size: 103 subjects Study Population: Children from 1 year to 18 years of age Comparator Product :Placebo solution, oral IMP Product : MGCND00EP1 (each ml of solution containing 100 mg of cannabidiol and 5 mg of (-)-trans-Δ9- tetrahydrocannabinol as active substance) from MGC PHARMACEUTICALS D.O.O. According to dosing scheme up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller) for 6 weeks titration and 6 weeks of treatment, oral administration

NCT ID: NCT04377425 Withdrawn - Stroke, Acute Clinical Trials

COVID-19 Prevalence and Cognitive Deficits in Neurological Patients

Neuro-Covid
Start date: May 7, 2020
Phase:
Study type: Observational

The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

NCT ID: NCT04344626 Withdrawn - Stroke Clinical Trials

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

Start date: July 16, 2018
Phase: N/A
Study type: Interventional

Refractory epilepsy, meaning epilepsy that no longer responds to medication, is a common neurosurgical indication in children. In such cases, surgery is the treatment of choice. Complete resection of affected brain tissue is associated with highest probability of seizure freedom. However, epileptogenic brain tissue is visually identical to normal brain tissue, complicating complete resection. Modern investigative methods are of limited use. An important subjective assessment during surgery is that affected brain tissue feels stiffer, however there is presently no way to determine this without committing to resecting the affected area. It is hypothesized that intra-operative use of a tonometer (Diaton) will identify abnormal brain tissue stiffness in affected brain relative to normal brain. This will help identify stiffer brain regions without having to resect them. The objective is to determine if intra-operative use of a tonometer to measure brain tissue stiffness will offer additional precision in identifying epileptogenic lesions. In participants with refractory epilepsy, various locations on the cerebral cortex will be identified using standard pre-operative investigations like magnetic resonance imagin (MRI) and positron emission tomography (PET). These are areas of presumed normal and abnormal brain where the tonometer will be used during surgery to measure brain tissue stiffness. Brain tissue stiffness measurements will then be compared with results of routine pre-operative and intra-operative tests. Such comparisons will help determine if and to what extent intra-operative brain tissue stiffness measurements correlate with other tests and help identify epileptogenic brain tissue. 24 participants have already undergone intra-operative brain tonometry. Results in these participants are encouraging: abnormally high brain tissue stiffness measurements have consistently been identified and significantly associated with abnormal brain tissue. If the tonometer adequately identifies epileptogenic brain tissue through brain tissue stiffness measurements, it is possible that resection of identified tissue could lead to better post-operative outcomes, lowering seizure recurrences and neurological deficits.

NCT ID: NCT04311242 Withdrawn - Epilepsy Clinical Trials

Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy

Start date: April 15, 2020
Phase:
Study type: Observational

Research study to look for bio markers in epilepsy patients on ketogenic diet

NCT ID: NCT04308252 Withdrawn - Clinical trials for Epilepsy in Children

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

Start date: March 15, 2020
Phase:
Study type: Observational

The purpose of this study is to determine stool microbiome composition and biomarkers that are differentially abundant and those that are associated with response to treatment (eg, anticonvulsant drugs).

NCT ID: NCT04283136 Withdrawn - Epilepsy Clinical Trials

A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

Start date: February 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study in Part 1, is to evaluate (under fasted conditions) the plasma pharmacokinetics (PK) of padsevonil (PSL) using 4 PSL product variants against a PSL reference tablet and in Part 2, to evaluate the PK of PSL using a PSL reference tablet under fed and fasted conditions at 200 mg and 400 mg.

NCT ID: NCT04282681 Withdrawn - Clinical trials for Epilepsy, Tonic-Clonic

XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)

XLTCS
Start date: March 16, 2020
Phase:
Study type: Observational

The primary objective of this study is to collect accelerometer data from subjects monitored in an EMU with concurrent video EEG.